A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects With Inadequately Controlled Asthma.
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2016
At a glance
- Drugs AMG-853 (Primary)
- Indications Asthma
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2012 Results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 19 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History